Wells Fargo upgrades UTHR from Equal Weight to Overweight

The Rating Action

Wells Fargo upgraded United Therapeutics (UTHR) to Overweight from Equal Weight on 2026-05-07. The rating change applies to the $24.9B market-cap biotech firm, with shares trading at $569.18 at the time of the analyst update.

Coverage History & Consensus

Prior to the May 7 upgrade, the broad UTHR analyst consensus had stayed static since March 1, 2026, split across 2 Strong Buy, 9 Buy, and 4 Hold ratings across 15 total covered firms, per monthly rating distribution data. Wells Fargo’s prior Equal Weight rating aligned with the Hold tier; its shift to Overweight places the firm in the Buy consensus group, expanding the total Buy-aligned ratings to 12 post-upgrade. No changes to the consensus breakdown were noted between April 1 and May 1, 2026.

Cross-Reference to Recent Insider & Fundamental Activity

The Wells Fargo upgrade coincided with multiple Form 4 insider transactions filed on 2026-05-07 for Paul Mahon, UTHR’s EVP & General Counsel. Mahon sold 8,299 shares across seven separate transactions at prices ranging from $582.86 to $597.54, generating approximately $4.87M in gross proceeds, and acquired 8,300 M-exempt shares at $146.03 each. Separately, UTHR posted Q1 2026 earnings on May 6, 2026, missing consensus revenue estimates by $15.9M (actual $781.5M vs. consensus $797.4M) and EPS by $1.18 (actual 5.82 vs. consensus 7.0), per the May 6 SEC 10-Q filing.

Unsignaled Context

This rating change omits three critical unstated details: 1) No disclosed price target was provided alongside the upgrade, per available research context; 2) It does not reflect the May 6 Q1 earnings miss, as the rating was published on the same day as insider filings but after the official earnings release; 3) The upgrade does not account for updated institutional positioning, as the latest 13F data (showing 849 institutional holders, a 101-quarter increase, holding 95.2% of UTHR’s float with total holdings valued at $20.3B) is from December 31, 2025, prior to both the earnings report and rating action.